Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Mach7 Technologies.
RELATED STOCKHEAD STORIES
News
Market Highlights: Records in sight for gold, Bitcoin; US chipmaker joins S&P500 and 5 small caps to watch
Health & Biotech
ScoPo’s Powerplays: Health stocks fall as tight hospital budgets hurt Nanosonics
Experts
MoneyTalks: Two ASX medical imaging stocks are put under microscope – both have big price targets
ScoPo’s Powerplays: ASX health stocks up but reporting season remains a bit chilly for some
ScoPo’s Powerplays: Nanosonics ‘in the doghouse’, but ASX health stocks are largely being good boys
Health & Biotech
ASX Health Stocks: CBL to advance DROVE wheelchair in US; Nanosonics dives 32pc after H1 update
Health & Biotech
ScoPo’s Powerplays: ASX health stocks feeling the love as Avita Medical kicks off 2024 strongly
Health & Biotech
ScoPo’s Powerplays: ASX healthcare 0.3% up as focus shifts to M&A activity in 2024
Experts
CRITERION: Missed the Pro Medicus boat? These cheaper alternatives scan well
Health & Biotech
ScoPo gives his NINE picks to fill the Christmas stocking with some ASX health stocks
Health & Biotech
ScoPo’s Powerplays: ASX healthcare up as ‘rising tide lifts all boats’
Health & Biotech
ASX Health Stocks: Mach7 signs $10m deal; Volpara agrees to $300m takeover from South Korean outfit
Health & Biotech
ScoPo’s Powerplays: Who fancies 22 minutes of exercise? And ASX health stocks are up (finally)
Health & Biotech
Q+A: Mach 7 CEO Mike Lampron on a barnstorming year and why AI isn’t the easy win it looks like
Experts
MoneyTalks: Wilsons initiates coverage on Mach7 with lofty price target, Goldman rates Judo Cap a buy
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but Dimerix up 150% on drug licensing deal
Health & Biotech